Stratification of Liver Stiffness according to eGFR in the MAFLD group.

Stratification of Liver Stiffness according to eGFR in the MAFLD group.

<p>Stratification of Liver Stiffness according to eGFR in the MAFLD group.</p>

Tallennettuna:

Bibliografiset tiedot
Päätekijä:	Zienab M. Saad (22676502) (author)
Muut tekijät:	Hesham K. H. Keryakos (22676505) (author), Hala A. Hassanin (22676508) (author), Mahmoud M. Higazi (22676511) (author), Manar M. Sayed (22676514) (author), Doaa E. Ismail (22676517) (author), Safaa M. Abdelhalim (21398199) (author)
Julkaistu:	2025
Aiheet:	Medicine Cell Biology Biotechnology Marine Biology Cancer Infectious Diseases Virology shear wave elastography patients remains underexplored mitigate progression risks higher liver stiffness 56 ± 17 43 ± 17 5 ± 28 ></ b >). ></ b >), ></ b >) shared metabolic abnormalities 9 ± 39 invasive fibrosis scores 45 ± 1 2 ± 5 mafld patients also dialysis ckd patients 108 ckd patients metabolic risk factors 5 ± 6 9 ± 1 5 ± 3 6 ± 1 xlink "> mafld xlink "> 5 %, b >< metabolic dysfunction 9 ml risk populations fibrosis severity advanced fibrosis 1 years 2 vs ckd severity 1 vs 6 vs study aimed sectional study participants stratified older age nafld score management strategies lower egfr integrated screening insulin resistance findings highlight diagnostic criteria bidirectional relationship apri score
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia

A. Violin plots showing eGFR distribution in MAFLD (red) vs. non-MAFLD (blue) groups.
Tekijä: Zienab M. Saad (22676502)
Julkaistu: (2025)

eGFR in the study participants.
Tekijä: Zienab M. Saad (22676502)
Julkaistu: (2025)

Grades of liver fibrosis in MAFLD group (grey) and non-MAFLD group (black).
Tekijä: Zienab M. Saad (22676502)
Julkaistu: (2025)

Medication-inclusive multivariable logistic regression for MAFLD.
Tekijä: Zienab M. Saad (22676502)
Julkaistu: (2025)

Multivariable logistic regression models for MAFLD predictors.
Tekijä: Zienab M. Saad (22676502)
Julkaistu: (2025)

Liver Stiffness and Fibrosis Grading by MAFLD Status.
Tekijä: Zienab M. Saad (22676502)
Julkaistu: (2025)

Proposed pathophysiological crosstalk between MAFLD and CKD.
Tekijä: Zienab M. Saad (22676502)
Julkaistu: (2025)

Liver Fibrosis Characteristics by CKD Stage in MAFLD Patients (n = 64).
Tekijä: Zienab M. Saad (22676502)
Julkaistu: (2025)

2D–shear-wave elastography example: MAFLD + CKD case (female, 57 years).
Tekijä: Zienab M. Saad (22676502)
Julkaistu: (2025)

2D–shear-wave elastography example: MAFLD + CKD case (male, 65 years).
Tekijä: Zienab M. Saad (22676502)
Julkaistu: (2025)

2D–shear-wave elastography example: non-MAFLD CKD case (male, 54 years).
Tekijä: Zienab M. Saad (22676502)
Julkaistu: (2025)

Receiver operating characteristic (ROC) curve analysis comparing the performance of non-invasive fibrosis scores in MAFLD patients.
Tekijä: Zienab M. Saad (22676502)
Julkaistu: (2025)

Comparison of Non-invasive Liver Fibrosis Scores.
Tekijä: Zienab M. Saad (22676502)
Julkaistu: (2025)

Demographic and Clinical Characteristics of Study Participants.
Tekijä: Zienab M. Saad (22676502)
Julkaistu: (2025)

Characteristic Flavaglines with Therapeutic Potential for Ischemic Stroke from <i>Aglaia perviridis</i>
Tekijä: Yan-Ping Zhang (432349)
Julkaistu: (2025)

Characteristic Flavaglines with Therapeutic Potential for Ischemic Stroke from <i>Aglaia perviridis</i>
Tekijä: Yan-Ping Zhang (432349)
Julkaistu: (2025)

Characteristic Flavaglines with Therapeutic Potential for Ischemic Stroke from <i>Aglaia perviridis</i>
Tekijä: Yan-Ping Zhang (432349)
Julkaistu: (2025)

Characteristic Flavaglines with Therapeutic Potential for Ischemic Stroke from <i>Aglaia perviridis</i>
Tekijä: Yan-Ping Zhang (432349)
Julkaistu: (2025)

Characteristic Flavaglines with Therapeutic Potential for Ischemic Stroke from <i>Aglaia perviridis</i>
Tekijä: Yan-Ping Zhang (432349)
Julkaistu: (2025)

Characteristic Flavaglines with Therapeutic Potential for Ischemic Stroke from <i>Aglaia perviridis</i>
Tekijä: Yan-Ping Zhang (432349)
Julkaistu: (2025)

Characteristic Flavaglines with Therapeutic Potential for Ischemic Stroke from <i>Aglaia perviridis</i>
Tekijä: Yan-Ping Zhang (432349)
Julkaistu: (2025)

Characteristic Flavaglines with Therapeutic Potential for Ischemic Stroke from <i>Aglaia perviridis</i>
Tekijä: Yan-Ping Zhang (432349)
Julkaistu: (2025)

Characteristic Flavaglines with Therapeutic Potential for Ischemic Stroke from <i>Aglaia perviridis</i>
Tekijä: Yan-Ping Zhang (432349)
Julkaistu: (2025)

Spearman correlation coefficient (r<sub>s</sub>) between echocardiographic measurements (i.e., left atrial:aortic root diameter; LA:Ao), markers of loss of GI barrier function (i.e., lipopolysaccharide; LPS), and cardiac (i.e., troponin) and systemic (i.e., cytokines) inflammation in 36 dogs with untreated myxomatous mitral valve disease (MMVD).
Tekijä: Maria C. Jugan (18928389)
Julkaistu: (2025)

Association between Exposures of Interest with Serum Lipopolysaccharide and Troponin Concentrations Based on Univariable Models‡ in 36 Client-owned Dogs with Untreated Myxomatous Mitral Valve Disease (MMVD).
Tekijä: Maria C. Jugan (18928389)
Julkaistu: (2025)

Association between Exposures of Interest with Serum Cytokine Concentrations Based on Univariable Models‡ in 36 Client-owned Dogs with Untreated Myxomatous Mitral Valve Disease (MMVD).
Tekijä: Maria C. Jugan (18928389)
Julkaistu: (2025)

Descriptive Statistics of Serum Concentrations of Cytokines, Lipopolysaccharides and Cardiac Troponin by Severity Stage in 36 Client-owned Dogs with Untreated Myxomatous Mitral Valve Disease (MMVD).
Tekijä: Maria C. Jugan (18928389)
Julkaistu: (2025)

Characteristics of children with SCD participating in the study, SSCAC, Elobeid, North Kordofan, Sudan, 2023, N: 123.
Tekijä: Weaam Abdallah (22683205)
Julkaistu: (2025)

Characteristics of parents of children with SCD participating in the study, SSCAC, Elobeid, North Kordofan, Sudan, 2023, N: 123.
Tekijä: Weaam Abdallah (22683205)
Julkaistu: (2025)

Baseline characteristics of caregivers of children with SCD participating in the study, SSCAC, Elobeid, North Kordofan, Sudan, 2023, N: 123.
Tekijä: Weaam Abdallah (22683205)
Julkaistu: (2025)

Distribution of Zarit burden scale items across caregivers of children with SCD, SSCAC, Elobeid, North Kordofan, Sudan, 2023, N: 123.
Tekijä: Weaam Abdallah (22683205)
Julkaistu: (2025)

Tribal affiliation of parents of children with SCD participating in the study, SSCAC, Elobeid, North Kordofan, Sudan, 2023, N: 123.
Tekijä: Weaam Abdallah (22683205)
Julkaistu: (2025)

Table 1_Association of triglyceride-glucose index and remnant cholesterol levels with liver fibrosis progression and disease severity in patients with non-alcoholic fatty liver disease: a cross-sectional study.docx
Tekijä: Qiong Duan (4693000)
Julkaistu: (2025)

Parameter values for four-pathway synaptic plasticity model.
Tekijä: Nicholas Hananeia (22683665)
Julkaistu: (2025)

Ion channels and membrane properties.
Tekijä: Nicholas Hananeia (22683665)
Julkaistu: (2025)

Distal LTP induced by simulated rMS is sustained by sodium dendritic spikes but less affected by inhibition than local electrical stimulation.
Tekijä: Nicholas Hananeia (22683665)
Julkaistu: (2025)

Voltage traces from local electrical and rMS TBS, recorded at the soma and distal apical tuft, account for the outcomes of synaptic plasticity.
Tekijä: Nicholas Hananeia (22683665)
Julkaistu: (2025)

The synaptic plasticity model reproduces distal LTP for local electric TBS and predicts proximal and distal LTP for rMS TBS.
Tekijä: Nicholas Hananeia (22683665)
Julkaistu: (2025)

Pharmacology in silico: rMS-induced LTP depends on dendritic sodium and calcium through voltage-gated calcium channels, as well as synaptic NMDA channels.
Tekijä: Nicholas Hananeia (22683665)
Julkaistu: (2025)

Presynaptic and postsynaptic weights change monotonically linearly over stimulus duration.
Tekijä: Nicholas Hananeia (22683665)
Julkaistu: (2025)

Cannot write session to /tmp/vufind_sessions/sess_on1sk2nssdss0j7bm6688ebkms